- Home
- KLC vs SPRY Comparison
KLC vs SPRY Comparison
Compare KLC & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLC
- SPRY
- Stock Information
- Founded
- KLC 1969
- SPRY 2015
- Country
- KLC United States
- SPRY United States
- Employees
- KLC N/A
- SPRY N/A
- Industry
- KLC
- SPRY Biotechnology: Pharmaceutical Preparations
- Sector
- KLC
- SPRY Health Care
- Exchange
- KLC NYSE
- SPRY Nasdaq
- Market Cap
- KLC 1.5B
- SPRY 1.4B
- IPO Year
- KLC 2024
- SPRY N/A
- Fundamental
- Price
- KLC $9.64
- SPRY $15.73
- Analyst Decision
- KLC Buy
- SPRY Strong Buy
- Analyst Count
- KLC 8
- SPRY 4
- Target Price
- KLC $25.50
- SPRY $28.75
- AVG Volume (30 Days)
- KLC 586.5K
- SPRY 1.2M
- Earning Date
- KLC 08-14-2025
- SPRY 08-05-2025
- Dividend Yield
- KLC N/A
- SPRY N/A
- EPS Growth
- KLC N/A
- SPRY N/A
- EPS
- KLC N/A
- SPRY N/A
- Revenue
- KLC $2,676,609,000.00
- SPRY $97,122,000.00
- Revenue This Year
- KLC $5.52
- SPRY N/A
- Revenue Next Year
- KLC $3.95
- SPRY $140.40
- P/E Ratio
- KLC N/A
- SPRY N/A
- Revenue Growth
- KLC 5.75
- SPRY 971120.00
- 52 Week Low
- KLC $9.79
- SPRY $7.55
- 52 Week High
- KLC $29.89
- SPRY $18.51
- Technical
- Relative Strength Index (RSI)
- KLC N/A
- SPRY 60.81
- Support Level
- KLC N/A
- SPRY $14.77
- Resistance Level
- KLC N/A
- SPRY $16.23
- Average True Range (ATR)
- KLC 0.00
- SPRY 0.73
- MACD
- KLC 0.00
- SPRY 0.12
- Stochastic Oscillator
- KLC 0.00
- SPRY 84.68
About KLC KINDERCARE LEARNING COMPANIES INC
KinderCare Learning Companies Inc is a private provider of early childhood education and care services (ECE) in the United States. It serves children ranging from 6 weeks to 12 years of age across its market footprint of around 1,480 early childhood education centers with a capacity of more than 194,000 children and contracts for more than 650 before- and after-school sites located in 40 states and the District of Columbia. Its segment derives revenue from providing early childhood education and care services at centers and before- and after-school sites.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.